Business
WellBiome® clinical trial on surgical outcomes
OptiBiotix Health plc has initiated a clinical study with Hull University Teaching Hospital NHS Trust to assess the impact of its WellBiome prebiotic on cardiac surgery outcomes and potential NHS cost savings. This double-blind, placebo-controlled study will involve up to 60 patients and evaluate the effects of six-week pre-operative supplementation on intensive care time, hospital stay duration, and post-operative complications, with a cost savings analysis also included. The company highlights WellBiome's patented mineral-enriched prebiotic fibre complex, designed to enhance gut microbiome diversity and offering various health benefits, as a response to growing consumer interest in gut health. Disclaimer*
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\" or the \"Group\")\n \n Clinical trial to evaluate the effect of WellBiome® on surgical outcomes and NHS cost savings\n \nOptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces the commencement of a clinical study with Hull University Teaching Hospital NHS Trust to determine the effect of taking WellBiome on cardiac surgery outcomes and potential NHS cost savings. \nA number of studies (Ardema 2019, Xia 2021) have suggested a decrease in microbial diversity and abundance post-surgery may increase hospital stays and that prebiotics like WellBiome, which increase microbial diversity and abundance and have systemic anti-inflammatory effects, may improve surgical outcomes.\nThis double blind, placebo-controlled study of up to 60 patients is designed to evaluate the effect of six-week pre-operative supplementation on time spent in intensive care, length of hospital stay, and the incidence of post-operative complications. The study includes a cost savings analysis to identify any potential cost savings to the NHS and inform the future use of prebiotics like WellBiome in improving health outcomes and cost savings.\nWellBiome is a patented mineral-enriched prebiotic fibre complex developed in collaboration with leading UK Universities to enhance gut microbiome diversity greater than single prebiotic fibres alone. WellBiome has a number of European and USA on pack health claims including: -\n· Nourishes beneficial bacteria throughout the entire gut to improve gut health\n· Contributes to improved bone health by aiding the absorption of essential minerals\n· Contributes to normal muscle function, including heart muscle\n· Supports normal brain health function and memory\n· Contribut...